Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15801MR)

This product GTTS-WQ15801MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15801MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8534MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ573MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ9702MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ10951MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ680MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ15903MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ10113MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ2665MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW